Endothelial damage inhibitors for improvement of saphenous vein graft patency in coronary artery bypass grafting: current evidence, clinical challenges and future directions.

Endothelial damage inhibitors for improvement of saphenous vein graft patency in coronary artery bypass grafting: current evidence, clinical challenges and future directions. Minerva Cardioangiol. 2020 Apr 23;: Authors: Sandner S, Pachuk CJ, Aschacher T, Milojevic M, Caliskan E, Emmert MY Abstract The saphenous vein graft (SVG) remains the most commonly used conduit in coronary artery bypass grafting (CABG). In light of this further research must be aimed at the development of strategies to optimize SVG patency and thereby improve both short- and long-term outcomes of CABG surgery. SVG patency in large part depends on the protection of the structural and functional integrity of the vascular endothelium at the time of conduit harvesting, including optimal storage conditions to prevent endothelial damage. This review provides an overview of currently available storage and preservation solutions, including novel endothelial damage inhibitors, and their role in mitigating endothelial damage and vein graft failure. PMID: 32326681 [PubMed - as supplied by publisher]
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research